Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study

被引：0

作者：

Jolanta Kunikowska

Dariusz Pawlak

Marianna I. Bąk

Beata Kos-Kudła

Renata Mikołajczak

Leszek Królicki

机构：

[1] Medical University of Warsaw,Nuclear Medicine Department

[2] National Centre for Nuclear Research,Radioisotope Centre POLATOM

[3] Medical University of Warsaw,Department of Internal Medicine and Diabetology

[4] Medical University of Silesia,Division of Endocrinology, Department of Pathophysiology and Endocrinology

来源：

Annals of Nuclear Medicine | 2017年 / 31卷

关键词：

PRRT; Y/; Lu-DOTATATE; Tandem therapy; Somatostatin receptor; Neuroendocrine tumors.;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：347 / 356

页数：9

共 139 条

[1] Kwekkeboom D(2000)Peptide receptor imaging and therapy J Nucl Med 41 1704-1713
[2] Krenning EP(2002)Combination of J Nucl Med 43 123P-124P
[3] de Jong M(2005)Y- and J Nucl Med 46 13S-17S
[4] De Jong HF(2011)Lu-labeled somatostatin analogs is superior for radionuclide therapy compared to Eur J Nucl Med Mol Imaging 38 1788-1797
[5] Bernard WA(2003)Y- or Eur J Nucl Med Mol Imaging 30 9-15
[6] Breeman BF(1958)Lu-labeled analogs only J Am Stat Assoc 53 457-481
[7] Bernard EP(2017)Combination radionuclide therapy using N Engl J Med 376 125-135
[8] Krenning M(1994)Lu- and J Nucl Med 35 152-156
[9] de Jong WA(2012)Y-labeled somatostatin analogs J Clin Oncol 30 1100-1106
[10] Breeman R(2014)Clinical results of radionuclide therapy of neuroendocrine tumours with Am J Nucl Med Mol Imaging 5 46-55